SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jan. 31, 2026 |
Jan. 31, 2025 |
Jan. 31, 2026 |
Jan. 31, 2025 |
|
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
| Total share-based compensation | $ 285,856 | $ 285,093 | $ 580,542 | $ 552,064 |
| Research, Development, and Clinical Trial Expenses [Member] | ||||
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
| Total share-based compensation | 79,016 | 50,839 | 162,447 | 83,557 |
| General and Administrative Expense [Member] | ||||
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
| Total share-based compensation | $ 206,840 | $ 234,254 | $ 418,095 | $ 468,507 |